A Phase IIIb Multicenter, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 May 2017
At a glance
- Drugs Pasireotide (Primary)
- Indications Acromegaly
- Focus Registrational; Therapeutic Use
- Acronyms SWITCH
- Sponsors Novartis
- 07 Jun 2017 Biomarkers information updated
- 28 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2017 Planned End Date changed from 1 Jan 2018 to 6 Aug 2018.